Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

被引：15

作者：

Loibl, Sibylle ^{[1
,2
]}

Huang, Chiun-Sheng ^{[3
,4
]}

Mano, Max S. ^{[5
]}

Mamounas, Eleftherios P. ^{[6
,7
]}

Geyer, Charles E. ^{[8
,9
]}

Untch, Michael ^{[10
,11
]}

Thery, Jean-Christophe ^{[12
]}

Schwaner, Ingo

Limentani, Steven ^{[13
]}

Loman, Niklas ^{[14
]}

Lubbe, Kristina ^{[15
]}

Chang, Jenny C. ^{[16
]}

Hatschek, Thomas ^{[17
]}

Tesarowski, David ^{[18
]}

Song, Chunyan ^{[18
]}

de Haas, Sanne Lysbet ^{[19
]}

Boulet, Thomas ^{[19
]}

Lambertini, Chiara ^{[19
]}

Wolmark, Norman ^{[8
,20
]}

机构：

[1] GBG, Neu Isenburg, Germany

[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] NSABP Fdn, Orlando, FL USA

[7] Orlando Hlth Canc Inst, Orlando, FL USA

[8] NSABP Fdn, Pittsburgh, PA USA

[9] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[10] AGO B, Berlin, Germany

[11] HELIOS Klinikum Berlin Buch, Berlin, Germany

[12] Ctr Henri Becquerel, Canc Ctr, Rouen, France

[13] Atrium Hlth, Charlotte, NC USA

[14] Skane Univ Hosp, Lund, Sweden

[15] Diakovere Henrietten Stift, Hannover, Germany

[16] Houston Methodist Canc Ctr, Houston, TX USA

[17] Karolinska Univ Hosp, Solna, Sweden

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Univ Pittsburgh, Pittsburgh, PA USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

NEOADJUVANT CHEMOTHERAPY; HER2; PROGNOSIS;

D O I：

10.1038/s41523-022-00477-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

引用

页数：6

共 50 条

[1] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Sibylle Loibl
Chiun-Sheng Huang
Max S. Mano
Eleftherios P. Mamounas
Charles E. Geyer
Michael Untch
Jean-Christophe Thery
Ingo Schwaner
Steven Limentani
Niklas Loman
Kristina Lübbe
Jenny C. Chang
Thomas Hatschek
David Tesarowski
Chunyan Song
Sanne Lysbet de Haas
Thomas Boulet
Chiara Lambertini
Norman Wolmark
npj Breast Cancer, 8
[2] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G.
Huang, C. -S.
Mano, M. S.
Loibl, S.
Mamounas, E. P.
Untch, M.
Wolmark, N.
Rastogi, P.
Schneeweiss, A.
Redondo, A.
Fischer, H. H.
Jacot, W.
Conlin, A. K.
Arce-Salinas, C.
Wapnir, I. L.
Jackisch, C.
DiGiovanna, M. P.
Fasching, P. A.
Crown, J. P.
Wuelfing, P.
Shao, Z.
Caremoli, E. Rota
Wu, H.
Lam, L. H.
Tesarowski, D.
Smitt, M.
Douthwaite, H.
Singel, S. M.
Geyer, C. E., Jr.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
[3] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
Mamounas, Eleftherios P.
Geyer, Charles E., Jr.
Huang, Chiun-Sheng
Mano, Max S.
Loibl, Sibylle
Untch, Michael
Wolmark, Norman
Rastogi, Priya
Schneeweiss, Andreas
Redondo, Andres
Fischer, Hans H.
Jacot, William
Conlin, Alison K.
Arce-Salinas, Claudia
Wapnir, Irene L.
Jackisch, Christian
DiGiovanna, Michael P.
Fasching, Peter A.
Crown, John P.
Wuelfing, Pia
Shao, Zhimin
Caremoli, Elena Rota
Wu, Haiyan
Lam, Lisa H.
Tesarowski, David
Smitt, Melanie
Douthwaite, Hannah
Singel, Stina M.
von Minckwitz, Gunter
SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
[4] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
Katherine A. Lyseng-Williamson
Drugs, 2020, 80 : 1723 - 1730
[5] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
Lyseng-Williamson, Katherine A.
DRUGS, 2020, 80 (16) : 1723 - 1730
[6] Trastuzumab emtansine for HER2-positive breast cancer
Venkatesan, Priya
LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
[7] Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
Katherine A. Lyseng-Williamson
Drugs, 2020, 80 : 2001 - 2001
[8] BUDGET IMPACT ANALYSIS OF TRASTUZUMAB EMTANSINE FOR RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN ARGENTINA
Penayo, N.
Peredo, S.
Olivera, M. S.
Weissberg, A.
Tellechea, F.
Saenz, V
VALUE IN HEALTH, 2020, 23 : S433 - S433
[9] Trastuzumab emtansine in HER2-positive metastatic breast cancer
Montemurro, Filippo
LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
[10] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Verma, Sunil
Miles, David
Gianni, Luca
Krop, Ian E.
Welslau, Manfred
Baselga, Jose
Pegram, Mark
Oh, Do-Youn
Dieras, Veronique
Guardino, Ellie
Fang, Liang
Lu, Michael W.
Olsen, Steven
Blackwell, Kim
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791

← 1 2 3 4 5 →